Tetsuya Mitsudomi

Has grant

Professor

Kindai University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

MET遺伝子のエクソン14欠失変異を有する肺腺癌に対する分子標的治療

Open Date: 2016-04-01

Close Date: 2019-03-31

Grant: Close

肺癌のキナーゼ阻害剤治療の新しい展開・獲得耐性の克服と新規標的の探索

Open Date: 2011-01-01

Close Date: 2011-12-31

Grant: Close

Analysis of lung adenocarcinoma according to molecular biological classification

Open Date: 2009-01-01

Close Date: 2011-12-31

Grant: Close

Molecular analysis of lung adenocarcinomas that do not have mutations in the EGFR pathway and development of therapeutic strategies against them

Open Date: 2008-01-01

Close Date: 2010-12-31

Grant: Close

Inhibition of metastasis and tetraspanin expression by the human monoclonal antibody directed to CD151 and RNA interference

Open Date: 2007-01-01

Close Date: 2008-12-31

Articles (51)

We investigated immunologic biomarkers that predict outcomes of patients with previously treated metastatic non‐small cell lung cancer who were enrolled in the J‐TAIL study, a prospective, observational study of atezolizumab monotherapy. Of 262 patients participating in the J‐TAIL exploratory study, peripheral blood mononuclear cells were obtained from 51 patients and analyzed by T‐cell fractionation analysis using Helios mass cytometry and serum proteomics analysis. Following treatment with atezolizumab, an increase in programmed cell death‐1 (PD‐1)‐expressing CD8 and CD4 T‐cell populations was observed. A more pronounced increase in PD‐1 expression was seen in T cells from patients whose progression‐free survival (PFS) was 100 days or longer compared with those with shorter PFS. The proximity extension assay, which is highly sensitive multiplex analysis technology that combines antibody‐based affinity assays with next‐generation sequencing, showed a significant increase in FOXO1, possibly in response to precursor‐exhausted T‐cell population activation. Immune‐related adverse events were associated with a high percentage of PD‐1‐positive cells on effector memory CD8 T cells, which was thought to be accompanied by extremely high CD8 T‐cell activation. Further analysis distinguished poor prognosis populations with significant differences in CD62L high Th7R and CXCR3 + component of Th7R (CXCR3 + Th7R) within the population with PFS < 50 days. Patients with low Th7R or CXCR3 + Th7R percentages prior to atezolizumab treatment had significantly poorer overall survival. These findings provide valuable insights regarding T‐cell kinetics and biomarkers in atezolizumab therapy and may offer promising directions for future research. Trial Registration: UMIN Clinical Trials Registry: UMIN000033133 and UMIN000035567; ClinicalTrials.gov : NCT03645330

Year:

2026

Figure S2. Results of the Reactome Pathway Analysis in each gene set; A, B, C, D, E, and F show the results of pathway analysis (cnet) for genes included in R1. R2. R3. N1, N2, and N3, respectively.

Year:

2025

Figure S4. List of genes of which the frequencies of mutation were different between recurrence group and control group. Green, red, and black indicate missense mutation, nonsense mutation, and multi-hits, respectively.

Year:

2025

Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.

Year:

2025

The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.

Year:

2025

Although pathologic stage I (pStage I) non–small cell lung cancer (NSCLC) has a good prognosis, some patients experience disease recurrence. Identification of prognostic markers for pStage I NSCLC may facilitate personalized perioperative treatment by expanding the candidates for adjuvant treatment. Patients with NSCLC with ground-glass opacity have excellent survival outcomes. Therefore, in this study, we explored prognostic biomarkers in pure solid nonsquamous NSCLC. We focused on nonsquamous NSCLC because the gene expression status is distinct from that of squamous cell carcinomas. RNA sequencing was performed on frozen tumor specimens from 33 patients with nonsquamous NSCLC with disease recurrence (recurrence group) and 33 counterparts (control group) extracted from patients without disease recurrence using propensity score matching (cohort 1). The candidate genes were further refined using an independent real-world cohort 2a ( N = 125) and validated in The Cancer Genome Atlas cohort. Through the analysis of cohort 1 and cohort 2a, we found that low expression of six genes ( BMP6 , KCNK3 , NFASC , OLFM1 , PEG3 , and TNXB ) was associated with disease recurrence. The prognostic impact of the six genes was confirmed using The Cancer Genome Atlas lung adenocarcinoma database. Multivariable proportional hazard analysis using the cohort 2a dataset revealed that the combination of BMP6 and OLFM1 status predicted recurrence-free survival. In conclusion, we found that low BMP6 / OLFM1 gene status is a potential biomarker to identify patients with high-risk pStage I pure solid nonsquamous NSCLC after pulmonary resection. Significance: The identification of subgroups with a high risk of disease recurrence among patients with NSCLC with pStage I is an important clinical issue. We explored genetic factors in patients with pStage I NSCLC with a high-risk clinical feature and identified low expression of OLFM1 and BMP6 genes as candidate biomarkers. Clinical application of these biomarkers, together with others, will open an opportunity to administer adequate adjuvant treatment for these high-risk patients.

Year:

2025

Recurrence-free survival of patients in Cohort 2a in the high expression group and low expression group for each gene ( A, BMP6 ; B, KCNK3 ; C, NFASC ; D, OLFM1 ; E, PEG3 ; and F, TNXB ).

Year:

2025

RFS of patients categorized by BMP6 and OLFM1 expression status. A and B, RFS in cohort 2a, a real-world cohort of patients with pStage I nonsquamous NSCLC whose tumors were analyzed using PolyA sequencing. C and D, RFS in the cohort of patients with EGFR mutations extracted from cohort 1 and cohort 2. H&H, high and high indicates higher expression of both BMP6 and OLFM1 ; H&L, high and low indicates higher expression for either of the BMP6 and OLFM1 and lower expression for the other; L&L, low and low indicates lower expression of both BMP6 and OLFM1 .

Year:

2025

Supplementary Figure 8. Circulating tumor DNA analysis data from Case 1. A, Allelic configuration analysis by liquid biopsy confirmed cis relationship between EGFR T790M and C797S mutations; no trans clones were detected. B, Serial changes in allelic frequency of all mutations detected in blood.

Year:

2025

Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EGFR 19Del/C797S, EGFR 19Del/T790M/C797S and patient-derived xenograft models. The patient-derived xenograft was derived from a patient with poorly-differentiated adenocarcinoma harboring an EGFR 19Del/T790M/C797S mutation. B, BBT-176 activity in a LU1235 EGFR 19Del patient-derived xenograft model. Abbreviations: PDX, patient-derived xenograft; PO, orally; QD, once daily.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (12)

Jin Seok Ahn

Professor

Samsung Medical Center

SOUTH KOREA
View details

Sun Min Lim

Yonsei University College of Medicine

SOUTH KOREA
View details

Taiguang Jin

Head of Discovery Biology

BrightPath Biotherapeutics

UNITED STATES
View details

Yasushi YATABE

Chief

National Cancer Center Research Institute

JAPAN
View details

Gwanghee Lee

-

SOUTH KOREA
View details

Kouya Shiraishi

Chief

National Cancer Center

JAPAN
View details

Hidenori Sato

Assistant Professor

Yamagata University

JAPAN
View details

MASAKI FUJITA

Professor

Kyushu University Hospital

JAPAN
View details

Dong-Wan Kim

Associate Professor

Seoul National University Hospital

SOUTH KOREA
View details

Koji Tamada

-

JAPAN
View details

Yasuhiro Tsutani

Kindai University Faculty of Medicine

JAPAN
View details

Ryuji Hamamoto

Division Chief

-

JAPAN
View details